[Temporary Announcement] Jiren Pharmaceutical: Announcement of Resolutions of the Eleventh Meeting of the Audit Committee of the Second Board of Directors

Announcement number: 2026-034

Securities code: 874919 Securities abbreviation: Jiren Pharmaceutical Sponsoring broker: China International Finance Securities

Anhui Jiren Pharmaceutical Co., Ltd.

Announcement of Resolutions of the Eleventh Meeting of the Audit Committee of the Second Board of Directors

The company and all members of the board of directors guarantee that the contents of the announcement are true, accurate and complete, and that there are no false records, misleading statements or major omissions, and bear individual and joint legal liability for the authenticity, accuracy and completeness of the contents.

1. Meeting convening and attendance

(1) Meeting status

1. Meeting time: May 11, 2026

2. Meeting method: √ On-site meeting √ Electronic communication meeting

3. Meeting place: company conference room

4. Time and method of issuing notice of board meeting: on April 30, 2026, by email, phone, or in writing.

5. Meeting host: Mr. Niu Jianjun, convener of the Audit Committee

6. Meeting attendees: some senior managers of the company

7. Explanation on the legality and compliance of the convening situation:

The convening, holding and voting procedures of this meeting complied with the relevant provisions of the "Company Law of the People's Republic of China" and other laws and regulations as well as the "Articles of Association".

(2) Meeting attendance

The meeting should be attended by 3 committee members, and 3 committee members should be present and authorized to attend the meeting.

2. Proposal review status

(1) Consideration and approval of the “Proposal on the Company’s Review Report for the First Quarter of 2026”

1. Contents of the motion:

Announcement number: 2026-034

In accordance with the requirements of relevant laws, regulations and normative documents, Daxin Accounting Firm (Special General Partnership) hired by the company reviewed the company's financial statements for the first quarter of 2026 and issued the "Review Report for the First Quarter of 2026 of Anhui Jiren Pharmaceutical Co., Ltd." (Daxin Yuezi [2026] No. 31-00002). For details, please refer to the "Review Report for the First Quarter of 2026" disclosed by the company on the National Small and Medium-sized Enterprises Share Transfer System Information Disclosure Platform (www.neeq.com.cn) on May 11, 2026 (announcement number: 2026-037).

2. Avoidance of voting:

This proposal does not involve related transactions and there is no need to avoid voting.

3. The voting results of the motion: 3 votes in favor; 0 votes against; 0 abstentions.

4. Opinions of the Audit Committee:

Agree to submit this proposal to the twelfth meeting of the second board of directors for consideration.

3. Documents for reference

"Resolution of the Eleventh Meeting of the Audit Committee of the Second Board of Directors of Anhui Jiren Pharmaceutical Co., Ltd."

Audit Committee of Anhui Jiren Pharmaceutical Co., Ltd.

May 11, 2026